| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Goh S et al. | An integrative expression vector for Actinosynnema pretiosum. | 2007 | BMC Biotechnol. | pmid:17956638 |
| Kan S et al. | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 | BMC Cancer | pmid:26475267 |
| Barok M et al. | Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. | 2018 | BMC Cancer | pmid:29720111 |
| Ricciardi GRR et al. | Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. | 2018 | BMC Cancer | pmid:29370839 |
| Tripathy D et al. | The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | BMC Cancer | pmid:24885258 |
| Tang R et al. | P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. | 2009 | BMC Cancer | pmid:19549303 |
| Mitsuya K et al. | Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. | 2016 | BMC Cancer | pmid:27377061 |
| Kmietowicz Z | NICE approves trastuzumab emtansine after deal with drug company. | 2017 | BMJ | pmid:28623237 |
| Dixon JM et al. | HER2 testing in patients with breast cancer. | 2012 | BMJ | pmid:22689887 |
| White C | NICE confirms advanced breast cancer drug is too expensive for NHS. | 2014 | BMJ | pmid:25106642 |
| Torres S et al. | Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. | 2014 | BMJ Case Rep | pmid:25123575 |
| Daniels B et al. | Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. | 2017 | BMJ Open | pmid:28119394 |
| Chen SC et al. | Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. | 2017 | Br J Clin Pharmacol | pmid:28733983 |
| Coiffier B et al. | A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. | 2016 | Br. J. Haematol. | pmid:27010483 |
| Ishitsuka K et al. | Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. | 2008 | Br. J. Haematol. | pmid:18279455 |
| Ghetti B | Induction of neurofibrillary degeneration following treatment with maytansine in vivo. | 1979 | Brain Res. | pmid:581857 |
| Ghetti B and Gambetti P | Comparative immunocytochemical characterization of neurofibrillary tangles in experimental maytansine and aluminum encephalopathies. | 1983 | Brain Res. | pmid:6354362 |
| Escrivá-de-Romanà S et al. | HER2-positive breast cancer: Current and new therapeutic strategies. | 2018 | Breast | pmid:29631097 |
| Barroso-Sousa R et al. | Biological therapies in breast cancer: common toxicities and management strategies. | 2013 | Breast | pmid:24144949 |
| Sakai H et al. | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. | 2018 | Breast Cancer | pmid:29700710 |
| Ahmed S et al. | HER2-directed therapy: current treatment options for HER2-positive breast cancer. | 2015 | Breast Cancer | pmid:25634227 |
| Higa GM | The microtubule as a breast cancer target. | 2011 | Breast Cancer | pmid:20862571 |
| Montemurro F | HER2 expression and efficacy of T-DM1. | 2014 | Breast Cancer Res. | pmid:25472666 |
| Perez EA et al. | Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. | 2014 | Breast Cancer Res. | pmid:24887458 |
| Barok M et al. | Trastuzumab emtansine: mechanisms of action and drug resistance. | 2014 | Breast Cancer Res. | pmid:24887180 |
| Barok M et al. | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. | 2011 | Breast Cancer Res. | pmid:21510863 |
| Baldassarre T et al. | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. | 2017 | Breast Cancer Res. | pmid:28974266 |
| Krop IE et al. | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. | 2016 | Breast Cancer Res. | pmid:26979312 |
| Diaby V et al. | Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. | 2017 | Breast Cancer Res. Treat. | pmid:28840424 |
| Le QA et al. | Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. | 2016 | Breast Cancer Res. Treat. | pmid:27572338 |
| Jacot W et al. | Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. | 2016 | Breast Cancer Res. Treat. | pmid:27167986 |
| Junttila TT et al. | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. | 2011 | Breast Cancer Res. Treat. | pmid:20730488 |
| Sibaud V et al. | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. | 2014 | Breast Cancer Res. Treat. | pmid:24929675 |
| Tanz R et al. | [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. | 2014 Jul-Aug | Bull Cancer | pmid:25091656 |
| Gonçalves A et al. | [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. | 2012 | Bull Cancer | pmid:23247898 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Monneret C and Florent JC | [Targeting of antitumor drugs with monoclonal antibodies]. | 2000 | Bull Cancer | pmid:11125291 |
| Guerin M et al. | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 | Bull Cancer | pmid:25790739 |
| Luduena RF et al. | N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041960 |
| Schibler MJ and Cabral FR | Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041962 |
| Johnson TA and Singla DK | Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. | 2018 | Can. J. Physiol. Pharmacol. | pmid:29842793 |
| Welslau M et al. | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. | 2014 | Cancer | pmid:24222194 |
| Moore KN et al. | Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. | 2017 | Cancer | pmid:28440955 |
| Franklin R et al. | A phase I-II study of maytansine utilizing a weekly schedule. | 1980 | Cancer | pmid:7214295 |
| Beeram M et al. | A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. | 2012 | Cancer | pmid:22648179 |
| Osieka R et al. | Chemotherapy of human colon cancer xenografts in athymic nude mice. | 1977 | Cancer | pmid:144557 |
| Li JY et al. | A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. | 2016 | Cancer Cell | pmid:26766593 |
| Chen SC et al. | Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). | 2017 | Cancer Chemother. Pharmacol. | pmid:29043411 |
| Li C et al. | Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. | 2017 | Cancer Chemother. Pharmacol. | pmid:29022084 |
| Douros J and Suffness M | New natural products of interest under development at the National Cancer Institute. | 1978 | Cancer Chemother. Pharmacol. | pmid:86390 |
| Lu D et al. | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. | 2014 | Cancer Chemother. Pharmacol. | pmid:24939213 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Wada R et al. | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. | 2014 | Cancer Chemother. Pharmacol. | pmid:25186956 |
| Rodon J et al. | Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. | 2008 | Cancer Chemother. Pharmacol. | pmid:18301896 |
| Girish S et al. | Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22271209 |
| Bender BC et al. | A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22886072 |
| Carter SK | New drugs under clinical evaluation in the United States. | 1978 | Cancer Chemother. Pharmacol. | pmid:155503 |
| Blum RH et al. | A therapeutic trial of maytansine. | 1978 | Cancer Clin Trials | pmid:757139 |
| T-DM1 aids patients with advanced breast cancer. | 2013 | Cancer Discov | pmid:24327714 | |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Interest in "smart bombs" explodes. | 2012 | Cancer Discov | pmid:23071018 | |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 | |
| Martin K et al. | The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. | 2014 | Cancer Immunol. Immunother. | pmid:24906866 |
| Yardley DA et al. | Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. | Cancer J | pmid:26389758 | |
| Lopus M | Antibody-DM1 conjugates as cancer therapeutics. | 2011 | Cancer Lett. | pmid:21481526 |
| English DP et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. | 2014 | Cancer Med | pmid:24890382 |
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Rao PN et al. | Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. | 1979 | Cancer Res. | pmid:455300 |
| Perrino E et al. | Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. | 2014 | Cancer Res. | pmid:24520075 |
| RÃos-Luci C et al. | Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. | 2017 | Cancer Res. | pmid:28687619 |
| Donoso JA et al. | Maytansine action on fast axoplasmic transport and the ultrastructure of vagal axons. | 1978 | Cancer Res. | pmid:77186 |
| Ootsu K et al. | Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro. | 1980 | Cancer Res. | pmid:6245801 |
| Ross S et al. | Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. | 2002 | Cancer Res. | pmid:11980648 |
| Tassone P et al. | In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. | 2004 | Cancer Res. | pmid:15231675 |
| Polson AG et al. | Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. | 2009 | Cancer Res. | pmid:19258515 |
| Lewis Phillips GD et al. | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. | 2008 | Cancer Res. | pmid:19010901 |
| Kovtun YV et al. | Antibody-maytansinoid conjugates designed to bypass multidrug resistance. | 2010 | Cancer Res. | pmid:20197459 |
| Reddy JA et al. | Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. | 2007 | Cancer Res. | pmid:17616697 |
| Henry MD et al. | A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. | 2004 | Cancer Res. | pmid:15520207 |
| Kovtun YV et al. | Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. | 2006 | Cancer Res. | pmid:16540673 |
| Erickson HK et al. | Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | 2006 | Cancer Res. | pmid:16618769 |
| Chari RV et al. | Immunoconjugates containing novel maytansinoids: promising anticancer drugs. | 1992 | Cancer Res. | pmid:1727373 |
| Sullivan AS et al. | Interaction of rhizoxin with bovine brain tubulin. | 1990 | Cancer Res. | pmid:2364385 |
| Yalowich JC | Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. | 1987 | Cancer Res. | pmid:2879622 |
| Tsuruo T et al. | Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. | 1986 | Cancer Res. | pmid:3753552 |
| Fellous A et al. | Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. | 1985 | Cancer Res. | pmid:3928146 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |
| Wang L et al. | STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. | 2018 | Cancer Sci. | pmid:30076657 |
| Wang H et al. | Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. | 2017 | Cancer Sci. | pmid:28388007 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Cabanillas F et al. | Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. | 1979 | Cancer Treat Rep | pmid:371803 |
| Chahinian AP et al. | Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. | 1979 Nov-Dec | Cancer Treat Rep | pmid:526928 |
| Creagan ET et al. | Phase II evaluation of maytansine in patients with advanced head and neck cancer. | 1979 Nov-Dec | Cancer Treat Rep | pmid:526939 |
| O'Connell MJ et al. | Phase II trial of maytansine in patients with advanced colorectal carcinoma. | 1978 | Cancer Treat Rep | pmid:356981 |
| Creech RH et al. | Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). | 1982 | Cancer Treat Rep | pmid:6282460 |
| Jaffrey IS et al. | Response to maytansine in a patient with malignant thymoma. | 1980 | Cancer Treat Rep | pmid:7379057 |
| Rosenthal S et al. | Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study. | 1980 Oct-Nov | Cancer Treat Rep | pmid:7459897 |
| Ahmann DL et al. | Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma. | 1980 Apr-May | Cancer Treat Rep | pmid:6448689 |
| Sieber SM et al. | Pharmacology of antitumor agents from higher plants. | 1976 | Cancer Treat Rep | pmid:136296 |